Dropless cataract care gains traction

Cataract surgery is one of the most standardized operations in medicine. The weird part is what comes after — patients often go home with a small chemistry set of drops, a taper schedule, and a lot of chances to mess it up. “Dropless” cataract care is the attempt to move that medication burden back into the operating room. Instead of asking patients to manage weeks of antibiotics and steroids, surgeons deliver some or all of that treatment during surgery itself. (ophthalmologytimes.com) ### What does “dropless” actually mean? It usually means the patient does not need the usual stack of self-administered postoperative eye drops. Surgeons can inject antibiotic and steroid medication into or around the eye during surgery, or use sustained-release options like dexamethasone inserts. The exact recipe varies by practice — intracameral moxifloxacin (ophthalmologytimes.com). (ophthalmologytimes.com) ### Why are surgeons interested now? Because the old system asks a lot from exactly the patients who struggle most with it. Cataract patients are often older. Some have arthritis, tremor, poor vision in the unoperated eye, low health literacy, or long travel times back to clinic. And eye-drop technique is worse than most people assume — one cost-analysis paper (ophthalmologytimes.com)to basically guaranteed. (ophthalmologytimes.com) ### Is there evidence this works? Yes — though the evidence is mixed by regimen, and that detail matters. A 2026 study in *Eye* looked at 3,307 surgeries and found sub-Tenon’s triamcinolone was noninferior to topical steroids for big postoperative concerns like pressure spikes above 35 mmHg, cystoid macular edema, and rebound iritis. A much larger Kaiser Perman(ophthalmologytimes.com)edema, iritis, and glaucoma-related events than topical regimens. (nature.com) ### So why isn’t everyone doing it? Because “dropless” is not one thing. It is a family of techniques, doses, and drug combinations. That makes adoption messy. Some surgeons are comfortable with intracameral antibiotics but still prefer topical steroids because drops can be increased, tapered, or stopped quickly. Community norms matter too — especially in the United States, where surgeons may worry that skipping drops still lo(nature.com)oach. (reviewofophthalmology.com) ### What’s the main tradeoff? Flexibility. A bottle of prednisolone is like a dimmer switch — you can turn treatment up or down as the eye declares itself. A depot steroid injection is more like setting the oven timer before you know exactly how dinner will cook. If inflammation runs hot, pressure rises, or cystoid macular edema emerges, the surgeon cannot simply “untake” the steroid already placed in the eye. That is the core reason patient selection keeps coming up. (reviewofophthalmology.com) ### Which patients are the best fit? Usually uncomplicated cataract cases where the biggest problem is drop burden, not unpredictable postop management. Surgeons especially like dropless strategies for patients with dexterity issues, trouble following complex schedules, or poor access to pharmacy and follow-up. But they may be more cautious in people with known steroid respo(reviewofophthalmology.com)ter postop titration. That caution shows up across both clinical reviews and practice discussions. (ophthalmologytimes.com) ### Does it save money too? Potentially, yes — and not by a little. A 2024 *Journal of Cataract & Refractive Surgery* cost analysis estimated that an injection-based regimen using intracameral moxifloxacin plus subconjunctival triamcinolone could cut per-eye costs by about 85% versus the lowest-cost topical regimen, with modeled annual savings up to $450 millio(ophthalmologytimes.com)ey explain why the idea keeps spreading. (pmc.ncbi.nlm.nih.gov) ### What changed in the story now? The shift is less about a single breakthrough drug and more about normalization. Recent reviews, 2025 ASCRS presentations, and 2026 practice pieces all point the same way — dropless care is moving from niche workaround to serious default option for selected cataract patients. The argument is no longer “can this be done?” It is “for whom is this the better postop plan?” (ophthalmologytimes.com) ### Bottom line? Dropless cataract care is gaining traction because it solves a very ordinary problem — patients are bad at complicated drop regimens. But the catch is real. Simpler for the patient can mean less adjustable for the surgeon. So this is not a revolution that replaces drops for everyone. It is a steady shift toward matching the medication plan to the patient in front of you.